Methods for treating CNS lesions
Provided herein are methods for repairing central nervous system, particularly brain, lesions in a subject comprising orally administering a carbonic anhydrase inhibitor.
1. A method of treating a brain lesion in a subject diagnosed with multiple sclerosis (MS) comprising orally administering a carbonic anhydrase inhibitor to the subject in an effective amount to increase cerebral perfusion.
2. The method of claim 1 , wherein the carbonic anhydrase inhibitor is acetazolamide (ACZ), dichlorphenamide, methazolamide, dorzolamide, or brinzolamide.
3. The method of claim 2 , wherein the carbonic anhydrase inhibitor is acetazolamide (ACZ).
4. The method of claim 1 , wherein the MS is relapsing-remitting, secondary progressive, or primary progressive MS.
5. The method of claim 1 , wherein the brain lesion is further defined as a subacute or chronic brain lesion.
6. The method of claim 1 , wherein the brain lesion is a T1 hypointense lesion.
7. The method of claim 1 , wherein the brain lesion is caused by cerebral hypoperfusion.
8. The method of claim 1 , wherein administering is for at least 2 months, 6 months, or 12 months.
9. The method of claim 1 , wherein between 1000 and 4000 mg of carbonic anhydrase inhibitor is administered daily.
10. The method of claim 1 , wherein the carbonic anhydrase inhibitor is formulated for immediate release.
11. The method of claim 1 , wherein the carbonic anhydrase inhibitor is formulated for sustained release.
12. The method of claim 1 , further comprising at least a second therapeutic.
13. The method of claim 12 , wherein the second therapeutic is a MS therapy.
14. The method of claim 13 , wherein the MS therapy is glatiramer acetate, interferon beta-1β, and/or interferon-1α.
15. The method of claim 13 , wherein the MS therapy is a bone marrow or stem cell transplant.
16. The method of claim 12 , wherein the second therapeutic is anti-inflammatory.
17. A pharmaceutical composition comprising between 1000 and 4000 mg of acetazolamide per dose, wherein the pharmaceutical composition is formulated for oral administration.
18. A method of treating brain lesion in a subject comprising orally administering an effective amount of a composition according to claim 17 to a subject.